The association between trimethoprim-sulfamethoxazole use and resistance among the major respiratory tract pathogens was investigated by comparing regional consumption of the drug to regional resistance in the following year in 21 central hospital districts in Finland. A total of 23,530 Streptococcus pneumoniae isolates, 28,320 Haemophilus influenzae isolates, and 14,138 Moraxella catarrhalis isolates were tested for trimethoprim-sulfamethoxazole susceptibility during the study period (1998)(1999)(2000)(2001)(2002)(2003)(2004). Among the S. pneumoniae isolates, a statistically significant connection was found between regional consumption and resistance. No statistically significant connection was found between regional trimethoprim-sulfamethoxazole use and resistance among H. influenzae and M. catarrhalis isolates. According to our results, it seems that only in pneumococci can the development of trimethoprimsulfamethoxazole resistance be influenced by restricting its use. However, trimethoprim-sulfamethoxazole remains an important antimicrobial agent because of its reasonable price. Hence, resistance to trimethoprim-sulfamethoxazole among these pathogens needs continuous monitoring.Sulfonamides were the first class of antimicrobial agents introduced into clinical use in 1935. Trimethoprim (TMP) was introduced in 1962, and the combination trimethoprim-sulfamethoxazole (SXT) was brought into clinical use in 1968. The antibacterial spectrum of the combination is directed at Escherichia coli, other species in the Enterobacteriaceae family, Staphylococcus aureus, Staphylococcus saprophyticus, and the principal respiratory tract pathogens Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.Hence, the most important fields of use of SXT combinations are in the treatment of urinary tract infections and upper respiratory tract infections. According to a point prevalence study conducted in the Finnish primary health care system, by indication, 81% of all SXT prescriptions were for respiratory tract infections and 15% were for urinary tract infections (21). Since it is a relatively inexpensive drug, this combination has been used widely in developing countries. There are also a few special indications for SXT use, such as the prophylaxis of Pneumocystis carinii infections among AIDS patients and the treatment of infections caused by Stenotrophomonas maltophilia (13).Emerging resistance among the major respiratory tract pathogens S. pneumoniae, H. influenzae, and M. catarrhalis has undoubtedly decreased the use of SXT. This resistance, however, varies worldwide. In the late 1990s, 31.9 to 88.6% of European and 24.2 to 89.4% of Asian S. pneumoniae isolates were susceptible to SXT. Among H. influenzae strains, a similar variation was noticed (22). According to a recent report from the United States, resistance among pneumococci is decreasing after peaking in 1999-2000 (9). A very small proportion of M. catarrhalis isolates, 0.1 to 2.6%, in the SENTRY surveillance program in 1997-1999 (12) showed resi...